Trayodashang Guggulu
Preclinical
Trayodashang Guggulu is one of 17 therapeutic programs targeting Knee Osteoarthritis. It is currently in Preclinical.
2
Indications
1
Total Trials
1
Active Trials
16
Competitors
Pipeline
Status by Indication[2][1]
Competition
Competitive Landscape
15 competitors in Knee Osteoarthritis
#DrugCompanyPhaseTrials
1Cymbalta
Jazz PharmaceuticalsApproved
Inulin and Sodium Chloride
BBlue Earth Diagnostics
Phase 2
Surgicel
PPeking University Third Hospital
Phase 3
PTP-01
DDoron Therapeutics Inc.
Phase 3
Medrol
PfizerPreclinical
Allocetra
EEnlivex Therapeutics Ltd.
Phase 2
Decadron
AAspen Global Incorporated
Preclinical
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Paracetamol
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Knee Osteoarthritis (Knee OA)1 trial
Holistic Healing for Knee Osteoarthritis: Comparing Integrated, Standard Medical, and Ayurvedic Care
Not yet recruiting·AAll India Institute of Medical Sciences, Jodhpur·Preclinical·NCT07768709·300 enrolled
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Trayodashang Guggulu. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Preclinical[1]